Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 5/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810451 | 0.85 | MAOB (0.66) | MAOBCYP3A4RAB9ASMPD1MAOA | |
| SCHEMBL18664184 | 0.83 | MAOB (0.81) | MAOBCYP3A4RAB9ASMPD1MAOA | |
| SCHEMBL29741480 | 0.83 | MAOB (0.81) | MAOBCYP3A4RAB9ASMPD1MAOA | |
| SCHEMBL23541189 | 0.83 | MAOB (0.59) | MAOBCYP3A4RAB9ASMPD1MAOA | |
| SCHEMBL23541194 | 0.83 | MAOB (0.59) | MAOBRAB9ASMPD1MAOAAPP | |
| SCHEMBL8509859 | 0.82 | FFAR1 (0.56) | MAOBMAOA | |
| SCHEMBL28553906 | 0.81 | MAOB (0.57) | MAOBCYP3A4RAB9ASMPD1MAOA | |
| SCHEMBL23566110 | 0.79 | MAOB (0.54) | MAOBCYP3A4RAB9ASMPD1MAOA | |
| SCHEMBL852236 | 0.79 | MEN1 (0.69) | MAOBRAB9ASMPD1SMN1; SMN2 | |
| SCHEMBL16841039 | 0.78 | MAOB (0.72) | MAOBCYP3A4RAB9ASMPD1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2014-07-17 | — | — | US | disclosed |
| US-8722930-B2 | Protease inhibitors | ORION CORPORATION (FI) | 2014-05-13 | — | — | US | disclosed |
| US-20120136002-A1 | PROTEASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-31 | — | — | US | disclosed |
| EP-2432556-A1 | PROTEASE INHIBITORS | Orion Corporation (FI) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133748-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | MAOB 187/4885CYP3A4 404/4885RAB9A 1915/4885 |
| US-20120136002-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | MAOB 187/4885CYP3A4 404/4885RAB9A 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.